← All Bicycle Therapeutics PLC filings

Bicycle Therapeutics PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BCYC
Bicycle Therapeutics PLC
10-K: Bicycle Therapeutics Reprioritizes Pipeline, Cuts Workforce Amid Rising Losses
Bicycle Therapeutics reported increased net losses in 2025 and announced a strategic reprioritization of its clinical pipeline, including discontinuing certain trials and a 30% workforce reduction, to focus on next-generation therapeutics.
NASDAQ
BCYC
Bicycle Therapeutics PLC
10-K: Bicycle Therapeutics Reports 2024 Financial Results and Provides Business Update
Bicycle Therapeutics' 2024 10-K filing highlights ongoing clinical trials for its Bicycle Toxin Conjugate (BTC) and Bicycle Tumor-Targeted Immune Cell Agonist (TICA) programs, strategic collaborations, and a focus on oncology and radiopharmaceutical development.
NASDAQ
BCYC
Bicycle Therapeutics PLC
10-K: Bicycle Therapeutics Outlines Share Structure and Governance in SEC Filing
Bicycle Therapeutics details its ordinary share structure, shareholder rights, and corporate governance policies in a recent SEC filing.